PPARα activation is essential for HCV core protein–induced hepatic steatosis and hepatocellular carcinoma in mice
Authors:
- 10 January 2008
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 118 (2) , 683-694
Abstract
Transgenic mice expressing HCV core protein develop hepatic steatosis and hepatocellular carcinoma (HCC), but the mechanism underlying this process remains unclear. Because PPARα is a central regulator of triglyceride homeostasis and mediates hepatocarcinogenesis in rodents, we determined whether PPARα contributes to HCV core protein–induced diseases. We generated PPARα-homozygous, -heterozygous, and -null mice with liver-specific transgenic expression of the core protein gene (Ppara+/+:HCVcpTg, Ppara+/–:HCVcpTg, and Ppara–/–:HCVcpTg mice. Severe steatosis was unexpectedly observed only in Ppara+/+:HCVcpTg mice, which resulted from enhanced fatty acid uptake and decreased mitochondrial β-oxidation due to breakdown of mitochondrial outer membranes. Interestingly, HCC developed in approximately 35% of 24-month-old Ppara+/+:HCVcpTg mice, but tumors were not observed in the other genotypes. These phenomena were found to be closely associated with sustained PPARα activation. In Ppara+/–:HCVcpTg mice, PPARα activation and the related changes did not occur despite the presence of a functional Ppara allele. However, long-term treatment of these mice with clofibrate, a PPARα activator, induced HCC with mitochondrial abnormalities and hepatic steatosis. Thus, our results indicate that persistent activation of PPARα is essential for the pathogenesis of hepatic steatosis and HCC induced by HCV infection.Keywords
This publication has 55 references indexed in Scilit:
- Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesisProceedings of the National Academy of Sciences, 2007
- Fenofibrate, a peroxisome proliferator‐activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liverLiver International, 2006
- Control of Peroxisome Proliferator-Activated Receptor Fate by the UbiquitinProteasome SystemJournal of Receptors and Signal Transduction, 2006
- Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis CJournal of Hepatology, 2005
- Steatosis: Co-factor in Other Liver Diseases *Hepatology, 2005
- Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodulesJournal of Hepatology, 2005
- Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damageHepatology, 2004
- Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionCancer, 2003
- In vivo stabilization of nuclear retinoid X receptor α in the presence of peroxisome proliferator‐activated receptor αFEBS Letters, 2003
- Peroxisome Proliferator-activated Receptor-α Regulates Lipid Homeostasis, but Is Not Associated with ObesityJournal of Biological Chemistry, 2001